Almirall S.A. Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 9, 2026 results vs estimates
Almirall S.A. Forecast
Almirall S.A. short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is negative (3 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 22.9% a year, a typical one-standard-deviation range is 10.39–11.09 over a week, 10.03–11.45 over a month and 8.2805–13.20 over a year. (Signals as of 4 Nov 2026.)
Almirall S.A. Price Chart
Almirall S.A. Factors
YoY −49.4%
YoY −34.1%
YoY −16.1%
YoY −62.8%
YoY −36.3%
YoY −23,819.8%
YoY +97.6%
YoY −12.2%
YoY +187.8%
YoY +26.3%
YoY −1.5%
YoY +0.9%
YoY −19.3%
YoY −14.3%
Almirall S.A. fundamentals: income statement, balance sheet & cash flow
Almirall S.A. reported revenue of €1.11bn and net income of €46.2m in FY2025, the year ended 31 December 2025 — revenue up 12.4% and net income up 355.3% on the prior year. Free cash flow was €134.3m. These figures are as reported in the filings, not restated: 23 fiscal years and 83 quarters of history, back to December 2003.
| EUR millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 1,108.1 | 985.7 | 894.5 | 863.2 | 827.2 |
| Cost of revenue | 651.4 | 218.0 | 317.4 | 182.5 | 171.6 |
| Gross profit | 456.6 | 767.7 | 577.1 | 680.8 | 655.6 |
| Research & development | 138.1 | 79.0 | 66.9 | 64.3 | 42.0 |
| Selling, general & admin. | — | 652.6 | — | — | — |
| Operating income | 67.7 | 36.1 | -5.3 | 46.9 | 105.4 |
| EBITDA | 218.9 | 173.8 | 114.3 | 157.0 | 132.3 |
| Interest expense | 17.9 | 16.4 | 15.4 | 7.4 | 13.0 |
| Pre-tax income | 74.4 | 26.5 | -17.2 | 31.0 | -9.1 |
| Income tax | 28.3 | 16.4 | 21.3 | 26.7 | 31.8 |
| Net income | 46.2 | 10.1 | -38.5 | 4.3 | -40.9 |
Download Almirall S.A. fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ALM.MC&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Almirall S.A.
Explore MacroFinance macro & markets research and analysis.
Almirall S.A. Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Almirall S.A.; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Almirall S.A.’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Almirall S.A. (Spain)
Almirall S.A. is a listed security in Spain. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on ALM Equity AB (publ)
Frequently asked questions
What is Almirall S.A.?
What is the latest Almirall S.A. price?
Is Almirall S.A. in an uptrend?
How volatile is Almirall S.A.?
What factors affect Almirall S.A.?
Which trading strategies trade Almirall S.A.?
How are Almirall S.A. returns analysed?
Where can I download free Almirall S.A. historical data?
Free Almirall S.A. historical data (last 10 years)
Browse or instantly download the last 10 years of Almirall S.A. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ALM.MC&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 10.26 |
| 2026-11-19 | 10.22 |
| 2026-11-18 | 10.32 |
| 2026-11-17 | 10.5 |
| 2026-11-16 | 10.64 |
| 2026-11-13 | 10.68 |
| 2026-11-12 | 10.78 |
| 2026-11-11 | 10.78 |
| 2026-11-10 | 10.56 |
| 2026-11-09 | 10.5 |
About this stock
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.